参考资料:
[1] UNION therapeutics announce results from the ADESOS Phase 2b study in atopic dermatitis confirming the potential of orismilast as a first-in-class safe and efficacious oral treatment. Retrieved September 25, 2024, from https://www.prnewswire.com/news-releases/union-therapeutics-announce-results-from-the-adesos-phase-2b-study-in-atopic-dermatitis-confirming-the-potential-of-orismilast-as-a-first-in-class-safe-and-efficacious-oral-treatment-302258828.html
[2] Genespire raises €46.6 million (~$52 million) in a Series B round to advance its first pediatric in-vivo gene therapy into the clinic. Retrieved September 25, 2024, from https://www.genespire.com/wp-content/uploads/2024/09/240925-Genespire-Series-B-press-release-FINAL.pdf
分享,点赞,在看,聚焦全球生物医药健康创新
参考资料:
[1] UNION therapeutics announce results from the ADESOS Phase 2b study in atopic dermatitis confirming the potential of orismilast as a first-in-class safe and efficacious oral treatment. Retrieved September 25, 2024, from https://www.prnewswire.com/news-releases/union-therapeutics-announce-results-from-the-adesos-phase-2b-study-in-atopic-dermatitis-confirming-the-potential-of-orismilast-as-a-first-in-class-safe-and-efficacious-oral-treatment-302258828.html
[2] Genespire raises €46.6 million (~$52 million) in a Series B round to advance its first pediatric in-vivo gene therapy into the clinic. Retrieved September 25, 2024, from https://www.genespire.com/wp-content/uploads/2024/09/240925-Genespire-Series-B-press-release-FINAL.pdf
分享,点赞,在看,聚焦全球生物医药健康创新